onc Videos

Videos

Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD

Videos

Managing Patients With Stage 1 HER2-Positive Breast Cancer

02/21/2024

Reshma Mahtani , DO;

Terry Mamounas , MD;

Jane Meisel , MD;

In this video, a panel of experts discuss the management of patients with stage 1, HER2-positive breast cancer, sharing data from several trials in this space, including the APT, ADEPT, and ATEMPT 2.0 trials.

In this video, a panel of...

02/21/2024

Oncology

Michael R Green, PhD, The University of Texas MD Anderson Cancer Center, Houston, Texas

Conference Coverage

Emerging Role of Epigenetic Therapies in Follicular Lymphoma and DLBCL Treatment

02/15/2024

Michael R. Green , PhD;

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Michael Green, PhD, discusses the role of epigenetic therapies in treating lymphoma.

At the 2023 Lymphoma, Leukemia &...

02/15/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Neoadjuvant vs Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer

02/15/2024

In this video, a panel of experts discuss approaches to neoadjuvant and adjuvant therapy for early-stage HER2-positive breast cancer and the value of achieving a pathological complete response from the surgical and medical oncology...

In this video, a panel of...

02/15/2024

Oncology

Videos

Next Steps for Validating CD5 IHC Positive DLBCL Types Benefiting From Targeted Therapies

02/15/2024

Alan Cooper , BS ;

Alan Cooper, lead study author, discussed follow-up research steps that would seek to validate CD5 immunohistochemistry positive diffuse large B-cell lymphoma types that could benefit from specific targeted therapies.

Alan Cooper, lead study author,...

02/15/2024

Oncology

Videos

Promising Advances in the Mantle Cell Lymphoma Treatment Landscape

02/13/2024

Eliza A. Hawkes , MD;

Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.

Eliza A Hawkes, MD, shares some...

02/13/2024

Oncology

Conference Coverage

Assessing Efficacy of Acalabrutinib-Rituximab Followed by Chemo and ASCT for Patients With Treatment-Naive MCL

02/13/2024

Eliza A. Hawkes , MD;

Eliza A Hawkes, MD, shares findings from the phase 2 WAMM trial, which assessed the use of acalabrutinib-rituximab followed by chemotherapy and autologous stem cell transplantation among young and fit patients with treatment-naive MCL.

Eliza A Hawkes, MD, shares...

02/13/2024

Oncology

Videos

Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

02/13/2024

Suzanne Lentszch , MD, PhD;

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.

At the 2023 Lymphoma, Leukemia &...

02/13/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Novel CD5 Biomarker Effective for Identifying DLBCL Subtypes Sensitive to BTK Inhibitor Therapy

02/08/2024

Justin Kline , MD;

Justin Kline, MD, discussed CD5 gene expression signature as a useful biomarker to identify diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies.

Justin Kline, MD, discussed CD5...

02/08/2024

Oncology

Videos

Safety, Tolerability of Capivasertib Plus Palbociclib and Fulvestrant Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

02/05/2024

Patrick Neven , MD, PhD;

Patrick Neven, MD, PhD, discusses updated phase 1b results from the CAPItello-292 study which demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive,...

Patrick Neven, MD, PhD,...

02/05/2024

Oncology

Andrea Apolo, MD, National Cancer Institute

Conference Coverage

Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer

02/05/2024

Andrea Apolo , MD;

At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.

At the 2024 ASCO GU Cancers...

02/05/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology